The global Cancer Biological Therapy Market is entering a transformative decade, fueled by breakthroughs in precision ...

The Chronic Lymphocytic Leukemia Market is set for significant expansion over the next decade. Valued at USD 5.4 billion in 2025, the market is projected to grow to USD 10.3 billion by 2035, ...

Black mamba venom's dual-paralysis effect can cause worsening symptoms even after antivenom treatment. Researchers found it ...

A promising new treatment for Lyme disease, a condition transmitted through tick bites, is in development and aims to offer ...

A novel cancer therapy developed at QIMR Berghofer is set to enter clinical development following a new collaboration and ...

THIRUVANANTHAPURAM: Taking a significant step forward in haemophilia care, the health department is set to establish a ...

Researchers evaluated whether interferon-α nasal spray reduces the incidence of COVID-19 or other respiratory viral infections among adults with cancer.

Week 48 endpoint results from the SOLSTICE Phase 2 clinical study evaluating tobevibart alone or in combination with elebsiran for chronic hepatitis delta to be presented– Vir Biotechnology to ...

Hospitalizations due to RSV cases in infants are reduced by up to 43% following the introduction of new maternal vaccines.

From bispecific engineering to clinically relevant data sourcing, evolving antibody technologies advance oncology therapeutics.

Leqembi ® Iqlik™, a subcutaneous (SC) formulation of lecanemab, is now available as a maintenance dosing regimen for the treatment of Alzheimer disease in patients with mild cognitive impairment or ...

"Lilly’s Omvoh benefit continues for four years in UC" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.